{
    "clinical_study": {
        "@rank": "31887", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to evaluate patients with metastatic castrate-resistant prostate cancer\n      (mCRPC) undergoing treatment with sipuleucel-T for evidence of treatment-associated immune\n      activation in lymph nodes and peripheral blood."
        }, 
        "brief_title": "Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a pilot study of mCRPC patients planning to undergo therapy with sipuleucel-T\n      immunotherapy.  Consenting patients will be randomized 3:1 between immediate sipuleucel-T\n      immunotherapy followed by lymph node biopsy (the post-treatment experimental group) or\n      immediate lymph node biopsy followed by sipuleucel-T immunotherapy (the pre-treatment\n      control group).  Peripheral blood will be collected before, during, and after treatment with\n      sipuleucel-T and evaluated for evidence of sipuleucel-T induced immune activation.  Lymph\n      nodes collected at biopsy will also be evaluated for evidence of sipuleucel-T induced immune\n      activation.  Patients will be followed for 3 months for safety and 6 months for disease\n      progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 18 years\n\n          2. ECOG performance status 0 or 1\n\n          3. Life expectancy of \u2265 6 months\n\n          4. Minimally-symptomatic or asymptomatic, castrate-resistant metastatic prostate cancer,\n             as evidenced by all of the following:\n\n               1. Histologically-confirmed diagnosis of adenocarcinoma of the prostate\n\n               2. Evidence of adequate androgen deprivation, as evidence by one of the following:\n\n                    -  Bilateral orchiectomy\n\n                    -  Ongoing LHRH agonist (e.g. leuprolide, goserelin) and serum testosterone\n                       <50 ng/dl\n\n                    -  Ongoing LHRH antagonist (e.g. degarelix) and serum testosterone <50 ng/dl\n\n               3. Evidence of prostate cancer resistance to castration, as evidenced by one of the\n                  following:\n\n                    -  2 consecutive PSA levels that are \u2265 50% above the PSA nadir achieved on ADT\n                       and obtained at least 1 week apart\n\n                    -  CT or MRI based evidence of disease progression (soft tissue or nodal)\n                       according to PCWG2 criteria or RECIST 1.1 criteria, or at least 1 new bone\n                       scan lesion as compared to the most immediate prior radiologic studies.\n\n               4. Presence of non-visceral metastases on imaging\n\n               5. Absence of major symptoms directly attributable to prostate cancer, with the\n                  following permissible exceptions:\n\n                    -  Ureteral obstruction secondary to pelvic or retroperitoneal lymphadenopathy\n\n                    -  Bladder outlet obstruction secondary to locally recurrent prostate cancer\n\n          5. Radiographic evidence of lymphadenopathy, defined as a lymph node greater than 1 cm\n             in diameter on axial imaging (CT or MRI or PET/CT)\n\n          6. Adequate laboratory parameters\n\n          7. A minimum of 4 weeks from any major surgery prior to registration\n\n        Exclusion Criteria:\n\n          1. Prior treatment with sipuleucel-T\n\n          2. Allergy to any component of sipuleucel-T\n\n          3. Inability to undergo leukapheresis\n\n          4. History of neuroendocrine variants of prostate cancer, including small cell carcinoma\n             of the prostate\n\n          5. Extensive prior surgery/radiation present that would render the biopsy highly complex\n             and the risk of intraoperative injury high\n\n          6. Any chronic medical condition requiring daily corticosteroids or other\n             immunosuppressants\n\n          7. Solid organ transplantation requiring immunosuppression\n\n          8. Visceral (e.g. lung, liver) metastases\n\n          9. Known brain metastases\n\n         10. History of spinal cord compression\n\n         11. Untreated/unstabilized pathologic long bone fractures\n\n         12. Other malignancy, except non-melanoma skin cancer, with a \u2265 30% probability of\n             recurrence within 24 months\n\n         13. Administration of any investigational therapeutic within 30 days of registration\n\n         14. Any condition which, in the opinion of the investigator, would preclude participation\n             in this trial"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036918", 
            "org_study_id": "Pro00047231"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "intervention_name": "Sipuleucel-T", 
                "intervention_type": "Drug", 
                "other_name": "Provenge"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "intervention_name": "Lymph Node Biopsy", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "lymphadenectomy", 
                    "lymph node dissection", 
                    "excisional lymph node biopsy"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "castrate resistant prostate cancer", 
            "metastatic", 
            "sipuleucel-T", 
            "lymphadenectomy", 
            "Excisional lymph node biopsy"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "contact": {
                "email": "patricia.creel@duke.edu", 
                "last_name": "Patricia Creel, RN", 
                "phone": "919-668-0635"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Brant Inman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Lymph Node Metastases in Men Undergoing Treatment With Sipuleucel-T for Metastatic Castrate-resistant Prostate Cancer", 
        "overall_contact": {
            "email": "patricia.creel@duke.edu", 
            "last_name": "Patricia Creel, RN", 
            "phone": "919-668-0635"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Brant Inman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "anti-PA2024 and anti-PAP immune response as measured by IFN\u03b3 ELISPOT done on lymph node-derived leukocytes and PBMCs", 
            "measure": "anti-PA2024 and anti-PAP immune response", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036918"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation", 
                "measure": "Serum anti-PA2024 antibody level", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation", 
                "measure": "serum anti-PAP antibody level", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}